Parallel session: Clinical developments in rare liver disease

 General hepatology

Strauss 3
English
Science/Research
13 April 2019 08:00 - 09:45


Presentations

PS-192 Lanreotide reduces liver growth in autosomal dominant polycystic kidney disease: Data from a 120-week randomized clinical trial
René van Aerts - Netherlands
13 April 2019 08:00 - 08:15

Abstract
PS-193 Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille Syndrome: 48-week interim efficacy analysis
Emmanuel Gonzales - France
13 April 2019 08:15 - 08:30

Abstract
PS-194 Effects of the ileal bile acid transport inhibitor A4250 on serum bile acids, pruritus and sleep in patients with Alagille syndrome: Phase 2 study results
Ulrich Baumann - Germany
13 April 2019 08:30 - 08:45

Abstract
PS-195 Predicting long-term outcome after surgical biliary diversion in Bsep-deficiency patients: Results from the NAPPED consortium
Daan van Wessel - Netherlands
13 April 2019 08:45 - 09:00

Abstract
PS-196 Efficacy and safety of sebelipase alfa over 144 weeks in a diverse population of children and adults with lysosomal acid lipase deficiency
Florian Abel - Switzerland
13 April 2019 09:00 - 09:15

Abstract
PS-197 Heterozygous alpha1-antitrypsin deficiency (Pi*MZ) is associated with increased liver stiffness and elevated liver enzymes in a multi-center European cohort
Carolin Victoria Heimes - Germany
13 April 2019 09:15 - 09:30

Abstract
PS-198 Fibroscan improves diagnosis of cystic fibrosis related liver disease
Jennifer Scott - United Kingdom
13 April 2019 09:30 - 09:45

Abstract